Section 4 of 6
Clinical evidence 273 evidence topics · 40 sources
Registry brief summary “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.” (opens the source at this quote in a new tab) Copy Flag
Objective stated in the AAAAI 2026 results poster 3.1.1.2 Location and study date
Sites, countries, and enrollment period in the publication Countries in each geographical region “Geographical region of North America includes Canada, Puerto Rico, and the USA; Europe includes Austria, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the UK; rest of world includes Argentina, Australia, Brazil, Hong Kong, Japan, Saudi Arabia, South Africa, South Korea, and Türkiye.” (opens the source at this quote in a new tab) Copy Flag
Patient association input on countries and sites Registry dates, status, and number of locations Trial initiation and topline timing reported by the company Target enrollment reached Topline announcement date
Crossover design, randomization, and stratification Masking and study drug packaging Washout between treated attacks Non-attack pharmacokinetic dose in adolescents Electronic patient-reported outcomes and attack qualification by the investigator Optional rollover to the open-label extension 3.1.1.4 Eligibility criteria
Inclusion criteria in the publication Exclusion criteria in the publication Registry inclusion criteria Registry exclusion criteria: organ function, CYP3A4 medicines, and prior therapies Qualifying attacks and exclusion of severe laryngeal attacks “Qualifying attacks were defined as either non-laryngeal attacks, with at least one symptom item score of 20 or more on the angioedema symptom rating scale (AMRA) assessment, which measures skin swelling, skin pain, and abdominal pain, as described below, or non-severe laryngeal attacks without breathing difficulties or stridor.” (opens the source at this quote in a new tab) Copy Flag
“Attacks of any severity (mild, moderate, and severe) were included, barring severe laryngeal attacks, consistent with other recent phase 3 trials of on-demand treatment in hereditary angioedema,” (opens the source at this quote in a new tab) Copy Flag
“due to the risks of random assignment to treatment with double-masked placebo.” (opens the source at this quote in a new tab) Copy Flag
“Adolescent participants with laryngeal attacks, regardless of severity, and adult participants with severe laryngeal attacks (those with symptoms of breathing difficulties or stridor) were instructed to immediately take their conventional on-demand therapy instead of the study drug and to seek medical care urgently.” (opens the source at this quote in a new tab) Copy Flag
“Attacks that did not meet the qualification criteria were treated with conventional on-demand therapy.” (opens the source at this quote in a new tab) Copy Flag
Registry treatment sequences and intervention Self-administration after investigator qualification Second capsule and rescue medication rules Registry definition of rescue medication
3.1.1.6.1 Rationale for using time to onset of symptom relief by patient global impression of change as the primary endpoint
Primary endpoint: definition in the publication Primary endpoint: registry definition and time frame PGI-C and PGI-S scales “The Patient Global Impression of Change (PGI-C) was used to evaluate the change in the hereditary angioedema attack symptoms at the time of the assessment compared with pre-treatment (last symptom assessment before study drug administration) and was scored on a seven-point Likert scale with possible responses of much better, better, a little better, same, a little worse, worse, and much worse.” (opens the source at this quote in a new tab) Copy Flag
“The Patient Global Impression of Severity (PGI-S) was used to evaluate the severity of hereditary angioedema attack symptoms at the time of the assessment and was scored on a five-point Likert scale with possible responses of none, mild, moderate, severe, and very severe.” (opens the source at this quote in a new tab) Copy Flag
“The PGI-C and PGI-S are validated instruments for evaluating patient-reported outcomes that have been previously used in clinical trials in hereditary angioedema to evaluate a patient's global perception of changes in and severity of their attack manifestations, respectively.” (opens the source at this quote in a new tab) Copy Flag
Assessment schedule after study drug Selection of PGI-C for the primary endpoint: mixed methods patient-reported outcome study PGI-C rating of a little better as a clinically meaningful milestone: patient interviews and phase 2 sebetralstat data Core outcome set for trials of acute treatment Conformance of RAPIDe-3 endpoints with the AURORA core outcome set Key secondary endpoints: definitions in the publication “Secondary efficacy endpoints were measured using the PGI-C, PGI-S, and AMRA instruments, and included: proportion of study drug-treated attacks reaching onset of symptom relief at 4 h (PGI-C), time to substantial symptom relief, defined as the time to a PGI-C rating of at least better for two consecutive timepoints within 12 h post-treatment, reduction in attack severity within 12 h (PGI-S), complete symptom resolution within 48 h (PGI-S), end of progression of symptoms within 12 h (PGI-C and AMRA), substantial symptom relief defined as time to 50% or greater reduction in AMRA composite score from pre-treatment for two consecutive timepoints within 12 h post-treatment, and almost complete or complete symptom resolution within 24 h (AMRA).” (opens the source at this quote in a new tab) Copy Flag
“Remaining secondary endpoints were the proportion of attacks achieving almost complete or complete symptom resolution within 24 h (AMRA), the proportion of attacks reaching complete symptom resolution with one capsule (PGI-S), and the proportion of attacks using rescue medication.” (opens the source at this quote in a new tab) Copy Flag
Key secondary endpoints: first six in the testing hierarchy Key secondary endpoints: registry definitions Key secondary endpoint: end of progression, definition and rationale Key secondary endpoint: end of progression, psychometric validation with RAPIDe-3 data Key secondary endpoints measured with the angioedema symptom rating scale Safety endpoints and the 3-day reporting window 3.1.1.7 Statistical analysis description
3.1.1.7.1 Number of participants (Planned and analyzed)
Sample size calculation and planned enrollment Planned enrollment stated by the company, May 2025 Registry actual enrollment Participants and attacks analyzed in each analysis set Safety analysis set by treatment received Observed placebo response compared with the sample size assumption 3.1.1.7.2 Description of analysis sets
Primary efficacy, expanded, and safety analysis sets Statistical tests for time-to-event and binary endpoints Multiplicity control by fixed-sequence gatekeeping Intercurrent events and missing data: composite variable strategy Supplementary analyses: per-protocol set and treatment policy strategy
3.1.1.8.1 Participant disposition
Screening, randomization, and treated attacks Randomized sequences and attacks treated in each sequence Trial closure before all participants treated two attacks 3.1.1.8.2 Baseline characteristics
All randomized participants: sex, age, and HAE with normal C1 inhibitor All randomized participants: demographic and disease characteristics, 134 participants Participants with at least one treated attack: demographic and disease characteristics by treatment, 113 participants Primary efficacy analysis set: demographic and disease characteristics, 88 participants Attack type, location, and severity at pre-treatment, 201 treated attacks “Of all 201 attacks treated with study drug, 181 (90%) were treated by participants with hereditary angioedema type 1, 16 (8%) by participants with hereditary angioedema type 2, and two (1%) by participants with normal C1 inhibitor (both carrying a variant in the plasminogen gene), respectively (table 1).” (opens the source at this quote in a new tab) Copy Flag
“For the 101 attacks treated with deucrictibant and 100 treated with placebo, respectively, the attack primary location was reported as peripheral (58 [57%] of 101 vs 54 [54%] of 100), abdominal (38 [38%] of 101 vs 42 [42%] of 100), and non-severe laryngeal (two [2%] of 101 vs none), and severity as mild (18 [18%] of 101 vs 12 [12%] of 100), moderate (60 [59%] of 101 vs 47 [47%] of 100), and severe or very severe (17 [17%] of 101 vs 29 [29%] of 100) at pre-treatment (appendix p 25).” (opens the source at this quote in a new tab) Copy Flag
“These distributions of attacks were consistent with the primary efficacy analysis set for both groups (appendix p 25).” (opens the source at this quote in a new tab) Copy Flag
3.1.1.8.3 Efficacy results
Primary endpoint: time to onset of symptom relief, primary efficacy analysis set of 88 participants with paired attacks Primary and secondary endpoints by PGI-C and PGI-S, primary efficacy analysis set of 88 participants with paired attacks Secondary endpoints by PGI-C and PGI-S: median times, primary efficacy analysis set “Endpoints of time to substantial symptom relief, reduction in attack severity, complete symptom resolution, and end of progression, as assessed by PGI-C or PGI-S, were also reached faster for deucrictibant-treated attacks than for placebo-treated attacks (p<0·0001 for all endpoints).” (opens the source at this quote in a new tab) Copy Flag
“Median times to each secondary endpoint for deucrictibant and placebo, respectively, were 2·85 h (95% CI 2·08 to 3·35) and more than 12 h (10·30 to >12) to substantial symptom relief, 2·41 h (1·70 to 2·98) and more than 12 h (12·34 to >12) to reduction in attack severity, 11·95 h (8·61 to 21·79) and more than 48 h (>48 to >48) to complete symptom resolution, and 17·47 min (16·27 to 19·17) and 228·67 min (61·82 to 599·60) to end of progression (figure 2B–E; table 2).” (opens the source at this quote in a new tab) Copy Flag
“The percentage of attacks meeting onset of symptom relief at 4 h post-treatment was 69 (83%) of 83 for deucrictibant and 24 (28%) of 87 for placebo (p<0·0001; table 2).” (opens the source at this quote in a new tab) Copy Flag
Company summary of the primary and secondary results, efficacy analysis of 88 participants with paired attacks Time to complete symptom resolution, placebo median: topline statement, December 2025, superseded in March 2026 End of progression median stated at NDA acceptance, July 2026 Secondary endpoints by AMRA, primary efficacy analysis set Attacks reaching each endpoint within its prespecified timeframe, primary efficacy analysis set Single capsule and second capsule use, primary efficacy analysis set of 88 paired attacks Rescue medication use, primary efficacy analysis set Complete symptom resolution with a single capsule at 24 hours, primary efficacy analysis set Sustained response and single-capsule use among responding attacks, primary efficacy analysis set of 88 participants Sensitivity and supplementary analyses, 113 participants with at least one treated attack Subgroups by age, HAE type, long-term prophylaxis, and attack location and severity, participants with at least one treated attack HAE with normal C1 inhibitor: two participants with one deucrictibant-treated attack each Regional subgroups, North America and Europe or rest of world: all participants with treated attacks Pharmacokinetics in adolescents: ten participants in a non-attack state 3.1.1.8.4 Health-related quality of life and patient-reported outcomes
Health-related quality of life as exploratory endpoints In-trial qualitative interviews: design and sample of 91 participants In-trial qualitative interviews: attack-related impacts on health-related quality of life In-trial qualitative interviews: on-demand treatments used before enrollment
Treatment-emergent adverse events, safety analysis set Overall and 3-day adverse event rates, safety analysis set Treatment-related adverse events Serious and severe adverse events Maximum severity grade of treatment-emergent adverse events, safety analysis set Laboratory, vital sign, and electrocardiogram findings and discontinuations Capsule ingestion during abdominal and laryngeal attacks
Summary
The authors stated that “Limitations of this trial include the lack of attack stratification according to location and severity”, and that a larger proportion of severe attacks was therefore observed in the placebo group: severe or very severe attacks at pre-treatment were 17 (17%) of 101 deucrictibant-treated and 29 (29%) of 100 placebo-treated attacks. Two non-severe laryngeal attacks were treated with deucrictibant and none with placebo.
Severe laryngeal attacks were not included, because of the risks of random assignment to double-masked placebo, and adolescents were instructed to treat laryngeal attacks of any severity with conventional on-demand therapy.
The sponsor ended the trial after the prespecified number of participants with paired attacks was reached and before all participants had treated two attacks. Of 134 enrolled participants, 113 treated at least one attack and 88 contributed paired attacks to the primary efficacy analysis. One participant randomized to the deucrictibant-placebo sequence was given placebo in error and treated no second attack.
Each participant treated at most one attack with deucrictibant in the crossover, and safety comparisons were descriptive. Treatment-emergent adverse events within 3 days of study drug were considered temporally clinically relevant.
Subgroups were small: ten (7%) enrolled participants were adolescents, five of them in the primary efficacy analysis set, and only two unpaired attacks were recorded in participants with hereditary angioedema with normal C1 inhibitor.
Eligibility required experience effectively using conventional on-demand therapy and excluded people older than 75 years, people with abnormal hepatic function or eGFR <60 ml/min/1.73 m2, users of strong CYP3A4 inhibitors or inducers, people with prior gene therapy, and pregnant or breastfeeding women.
Use of rescue or selected prohibited medication was counted as treatment failure, and missing data at the end of follow-up were handled by right censoring without imputation.
Health-related quality of life outcomes were exploratory endpoints planned for separate publication.
Study aim in the publication Primary objective: symptom relief within 4 hours 3.1.2.2 Location and study date
Registry dates and number of locations Sites, regions, and screening and randomization dates in the publication “Patients were recruited from 38 sites, including university hospitals and accredited angioedema centres, in North America, Europe, and Israel (appendix pp 2–4).” (opens the source at this quote in a new tab) Copy Flag
“Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1).” (opens the source at this quote in a new tab) Copy Flag
Countries and sites at topline, December 2022 Sites reported in a March 2023 presentation Trial start and topline timing U.S. clinical hold in August 2022 and partial lift for RAPIDe-1
Two-part, randomized, double-blind, placebo-controlled, crossover, dose-ranging design Randomization to dose cohorts and crossover treatment sequences Masking and identical capsules Investigator confirmation of each attack by remote consultation Safety visits, end-of-trial visit, and electronic attack diary Rollover to CHAPTER-1 or RAPIDe-2 after the trial 3.1.2.4 Eligibility criteria
Inclusion criteria in the publication: age, HAE type, and attack frequency Long-term prophylaxis exclusion and washout periods Hepatic and renal function, CYP3A4 inhibitors or inducers, and pregnancy Registry key inclusion and exclusion criteria Attack-level criteria: qualifying and excluded attacks
Part 1 single dose in the attack-free state and Part 2 home self-administration Doses and crossover sequences per dose cohort Registry interventions: soft capsules and matching placebo Formulation: PHVS416 softgel capsule Rescue medication permitted from 4 hours after study drug Dose selection based on the bradykinin challenge and EC85
3.1.2.6.1 Rationale for using change in the 3-Symptom composite visual analogue scale score as the primary endpoint
Primary endpoint: definition and assessment schedule in the publication “The primary efficacy endpoint was change in the patient-reported composite VAS score (VAS-3)” (opens the source at this quote in a new tab) Copy Flag
“The VAS-3 was calculated as the mean of three individual VAS scores assessing the three major hereditary angioedema symptoms: skin swelling, skin pain, and abdominal pain. Each symptom was rated separately on a 0–100 scale, where 0 indicated no swelling (for skin swelling) or no pain (for skin and abdominal pain), and 100 indicated extreme swelling or extreme pain, respectively. Scores were recorded before treatment, every 30 min (± 10) up to 4 h, and at 5 h (± 0·5), 6 h (± 0·5), 8 h (± 1), 24 h (± 4), and 48 h (± 6) post-treatment thereafter.” (opens the source at this quote in a new tab) Copy Flag
Primary endpoint: registry definition Electronic, numerically assisted capture of the VAS-3 Authors' rationale: 4-hour timepoint and scales used in earlier on-demand trials Sponsor rationale: VAS in icatibant and recombinant C1 esterase inhibitor approvals and the FDA outcome assessment compendium Three-symptom VAS in the icatibant FAST-1 and FAST-2 trials Content validity of HAE VAS instruments VAS-3 in earlier on-demand trials and its adaptation to electronic AMRA instruments Key secondary endpoints: time-to-event VAS-3 outcomes, MSCS, and TOS Key secondary endpoint: registry definition of almost complete or complete symptom relief Key secondary endpoints: MSCS and TOS instruments Key secondary endpoints: validation and minimally important differences of TOS and MSCS Other secondary endpoints: rescue medication use and lower-ranked endpoints including TSQM Other secondary endpoint: TSQM registry definition Post hoc endpoint: time to end of progression 3.1.2.7 Statistical analysis description
3.1.2.7.1 Number of participants (Planned and analyzed)
Sample size and power assumptions Registry enrollment and participants randomized per dose cohort Participants and attacks in the primary efficacy analysis Participants and attacks in the safety analysis set Attacks in the final analysis and participants with pharmacokinetic sampling 3.1.2.7.2 Description of analysis sets
Modified intention-to-treat and per-protocol analysis sets Safety and pharmacokinetic analysis sets Primary analysis before all participants had three attacks, and descriptive final analysis Primary endpoint model: mixed model for repeated measures Prespecified sensitivity analyses of the primary endpoint Multiplicity control for the 20 mg and 30 mg branches, and descriptive 10 mg analyses Time-to-event and rescue medication analyses Registry caveat on Kaplan-Meier medians
3.1.2.8.1 Participant disposition
Screening, randomization, and follow-up in the primary analysis set “Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1). For the primary analysis set, the median follow-up was 130·0 (IQR 92·5–212·5) days for deucrictibant 10 mg, 166·5 (80·0–275·0) days for deucrictibant 20 mg, and 172·0 (65·0–242·0) days for deucrictibant 30 mg. Similar numbers of patients across the groups completed Part 1, treated one, two, or three attacks in Part 2, and completed post-attack visits before the primary analysis cutoff (figure 1).” (opens the source at this quote in a new tab) Copy Flag
Registry participant flow by randomized dose cohort, Part I and Part II Follow-up in the final analysis 3.1.2.8.2 Baseline characteristics
Demographics and HAE characteristics by dose cohort, full analysis set Attack frequency and prior HAE medication, full analysis set Registry baseline age and ethnicity, full analysis set Sex and race, mITT analysis set of 62 participants Pre-treatment VAS-3 scores of treated attacks, mITT analysis set 3.1.2.8.3 Efficacy results
Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data Primary endpoint: sensitivity analyses and VAS-3 course over time Primary endpoint: post hoc pooled deucrictibant doses versus placebo Key secondary endpoints: multiplicity-controlled results for 20 mg and 30 mg Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set Symptom resolution within 24 hours without rescue medication, deucrictibant 20 and 30 mg versus placebo Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set Rescue medication use in the top-line data, December 2022, deucrictibant 10, 20, and 30 mg versus placebo Time to onset of primary symptom relief by 30% VAS reduction, registry results, participants with evaluable data Post hoc time to end of progression, deucrictibant 10, 20, and 30 mg versus placebo, 147 attacks in 62 participants Results by attack location: abdominal, peripheral, and combined attacks Time from symptom onset to treatment Final analysis of 165 attacks Company characterization of efficacy across all three doses Part 1 pharmacokinetics relative to EC85, 12 participants with sampling 3.1.2.8.4 Health-related quality of life and patient-reported outcomes
TSQM domain scores at 48 hours, registry results, participants with evaluable data TSQM reporting in the publication
Part 1 adverse events in the attack-free state, safety analysis set of 72 participants Part 2 adverse events in treated attacks, safety analysis set of 156 attacks Treatment-emergent adverse events within 5 days by part and dose, safety analysis set Severe, serious, and discontinuation events, laboratory, ECG, and vital signs Registry adverse event counts by part and treatment group Treatment-related adverse events in the top-line data and a congress poster Absence of injection-site reactions with oral administration
Summary
The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.
Registry objective: long-term safety and efficacy of on-demand treatment Main and secondary objectives in the EU register record Objective of the Part A final analysis Objective of the post hoc upper airway and laryngeal attack analysis Objective of the post hoc durability-of-response analysis Purpose stated by the company 3.1.3.2 Location and study date
Registry dates, status, and number of locations Sites anticipated in the European Economic Area Study status in the annual report
Two parts: dose-blinded Part A and open-label Part B Part A design and treatment of upper airway attacks Phase 2/3 long-term extension with scheduled assessments Study code: C303 in the registry, C201 in one annual report heading 3.1.3.4 Eligibility criteria
Part A: adults who completed RAPIDe-1, without long-term prophylaxis Registry inclusion: participants from RAPIDe-1 and RAPIDe-3, including adolescents Registry inclusion: treatment-naive adults with HAE with normal C1 inhibitor Registry exclusion: lanadelumab, washout periods, and strong CYP3A4 modulators Part B: stable long-term prophylaxis permitted EU register exclusion: QTcF prolongation
Registry arms: blinded dose in Part A, open-label soft capsules in Part B Second dose and rescue medication rules Part A results: combined dose group of 10, 20, and 30 mg
3.1.3.6.1 Rationale for using treatment-emergent adverse events as the primary endpoint
Primary endpoint: long-term safety of on-demand use Registry primary outcome measures and time frame Safety components of the primary endpoint Secondary endpoints in the registry Censoring rules for rescue medication Post hoc endpoint: durability of response and symptom reoccurrence Post hoc definition of upper airway attacks 3.1.3.7 Statistical analysis description
3.1.3.7.1 Number of participants (Planned and analyzed)
Planned enrollment in the registry Planned number of participants in the EU register record Part A analyzed: 465 attacks in 19 participants Upper airway attacks: 14 attacks in seven participants 3.1.3.7.2 Description of analysis sets
Safety and modified intention-to-treat analysis sets (Part A) Evaluable attacks for PGI-C and PGI-S endpoints Baseline values carried from RAPIDe-1
3.1.3.8.1 Participant disposition
Part A: no discontinuations, withdrawals, or deaths due to adverse events 3.1.3.8.2 Baseline characteristics
Part A participants, combined dose group (N=19) Participants with and without upper airway attacks 3.1.3.8.3 Efficacy results
Median time to key efficacy endpoints, Part A (465 attacks) Median times reported in the annual report Proportion of attacks achieving key endpoints, evaluable attacks (457 PGI-C, 449 PGI-S) Attacks treated with a single dose and rescue medication use, evaluable attacks (457) Attacks treated with a single dose, all treated attacks (465) Durability of response after a single dose, post hoc analysis Upper airway attacks compared with non-upper airway attacks, post hoc analysis Upper airway attacks: proportions achieving endpoints, single dose, and rescue use Company summary of Part A efficacy 3.1.3.8.4 Health-related quality of life and patient-reported outcomesNo evidence found.
Adverse events within 3 days of study drug, Part A (N=19; 465 attacks) Serious adverse event unrelated to treatment, and laboratory, vital sign, and ECG findings Safety across dose groups in the annual report Safety in upper airway and non-upper airway attacks
Summary
RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
Upper airway results rest on 14 attacks in seven participants.
Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.
Safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants Proof of mechanism through bradykinin challenge 3.1.4.2 Location and study date
Entry into clinical development with a phase 1 trial in 2019 Completion reported in November 2020 Study status in the annual report
Double-blind, placebo-controlled, single ascending dose, first-in-human design Cohorts: pharmacokinetic part 1 and pharmacodynamic part 2 Bradykinin challenge schedule Study code: C001 in the annual report, PHA121-C001 in the registration statement 3.1.4.4 Eligibility criteria
Single oral doses as an oral solution Bradykinin challenge cohorts: 12 and 22 mg Fed condition: 22 mg after a high-calorie, high-fat breakfast
3.1.4.6.1 Rationale for using safety and tolerability as the primary endpoint
Safety and pharmacokinetics assessed through 72 hours Bradykinin challenge as a surrogate for dose selection Pharmacodynamic outcome definition Use of the bradykinin challenge results for later studies 3.1.4.7 Statistical analysis description
3.1.4.7.1 Number of participants (Planned and analyzed)
Participants receiving deucrictibant and placebo Bradykinin challenge participants 3.1.4.7.2 Description of analysis sets
Pharmacokinetic and pharmacodynamic modeling of the bradykinin challenge cohorts Pharmacokinetic summary statistics
3.1.4.8.1 Participant disposition
No withdrawals due to adverse events 3.1.4.8.2 Baseline characteristicsNo evidence found.
3.1.4.8.3 Efficacy results
Pharmacokinetics: rapid absorption, dose proportionality, and half-life Pharmacokinetic parameters by dose (N=6 per dose) Time to and duration above therapeutic threshold concentrations Bradykinin challenge: potency relative to icatibant Bradykinin challenge: modeled duration of effect compared with icatibant 30 mg Authors' conclusions on the bradykinin challenge 3.1.4.8.4 Health-related quality of life and patient-reported outcomesNo evidence found.
Adverse events by dose group Adverse event incidence with deucrictibant and placebo Treatment-related gastrointestinal adverse events and blood pressure Pooled safety across two single ascending dose studies (1 to 50 mg)
Summary
PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
Safety was followed for 72 hours after a single dose.
The results are reported in two posters described in a company press release and in the company's registration statement.